ArticleGeneral hospital psychiatry
Comparative effectiveness of lorazepam versus diazepam for acute catatonia: A retrospective analysis.
Article in General hospital psychiatry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveCatatonia is a neuropsychiatric disorder that can respond rapidly to treatment with benzodiazepines. Historically, lorazepam is the most used agent for "the lorazepam challenge test" (LCT), but comparative evidence for alternative benzodiazepines remains limited. A temporary intravenous (IV) lorazepam shortage within our health system created a natural experiment by restricting access to lorazepam. We use this natural experiment to compare a single dose of IV diazepam vs. IV lorazepam for the acute treatment of catatonia in a LCT.
methodsRetrospective comparative effectiveness study of adults with clinically diagnosed catatonia treated during a period of IV lorazepam shortage (July-November 2025) who received IV diazepam and had Bush-Francis Catatonia Rating Scale (BFCRS) assessments before and after benzodiazepine administration. These patients were compared with an equal number of patients treated with IV lorazepam in adjacent non-shortage periods. The primary outcome was change in BFCRS following a single dose of benzodiazepine. Between-group differences in change scores were analyzed using Welch's t-test, with Mann-Whitney U test sensitivity analysis.
resultsTwenty patients met inclusion criteria (10 diazepam; 10 lorazepam). Baseline BFCRS severity was similar between groups (overall mean 15.6 ± 6.2). Across the full cohort, benzodiazepine administration produced a large within-subject improvement in catatonia severity (mean BFCRS change -5.8 ± 5.0; p < 0.001; Hedges' g = 1.12). Mean BFCRS change was -6.8 ± 6.6 in the diazepam group and - 4.9 ± 2.6 in the lorazepam group. The between-group difference in improvement (diazepam - lorazepam) was -1.90 BFCRS points (95% CI -6.83 to +3.03), corresponding to a negligible effect size and was not statistically significant (p = 0.42). Any improvement occurred in 9 diazepam-treated patients and all lorazepam-treated patients.
conclusionsIn this quasi-experimental cohort, a single dose of IV diazepam produced short-term reductions in catatonia severity comparable in magnitude to a single dose of IV lorazepam in the LCT. Although underpowered to establish equivalence, these findings provide preliminary empirical support for IV diazepam as a viable acute treatment option when lorazepam is unavailable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.